Inovio Pharmaceuticals logo

Inovio PharmaceuticalsNASDAQ: INO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

08 December 1998

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$138.91 M
-91%vs. 3y high
48%vs. sector
-vs. 3y high
-vs. sector
-60%vs. 3y high
49%vs. sector
234.68
-63%vs. 3y high
96%vs. sector

Price

after hours | Fri, 01 Nov 2024 23:46:42 GMT
$5.35+$0.11(+2.09%)

Dividend

No data over the past 3 years
$100.80 K$100.00 K
$100.80 K-$32.24 M

Analysts recommendations

Institutional Ownership

INO Latest News

INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP
prnewswire.com21 October 2024 Sentiment: POSITIVE

American Association for Cancer Research (AACR) Special Conference: Tumor Immunology and Immunotherapy : New immunology data showed ability of INO-3107 to induce an antigen-specific T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma International Society of Vaccines Conference : Full safety and efficacy data from Phase 1/2 clinical study in patients with Recurrent Respiratory Papillomatosis (RRP) indicated that INO-3107 was well tolerated and immunogenic; 81% of patients in the trial required fewer surgeries post-treatment when compared to baseline PLYMOUTH MEETING, Pa. , Oct. 21, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the presentation of new data at scientific conferences for its lead candidate, INO-3107, for which the company is preparing a Biologics License Application for targeted submission in mid-2025 under the U.S. Food and Drug Administration's Accelerated Approval Pathway Program.

INOVIO Reports Inducement Grants Under Inducement Plan
prnewswire.com02 October 2024 Sentiment: POSITIVE

PLYMOUTH MEETING, Pa. , Oct. 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made equity grants to certain employees under its 2022 Inducement Plan (the "Inducement Plan").

INOVIO to Present at Upcoming Scientific Conferences
prnewswire.com01 October 2024 Sentiment: POSITIVE

PLYMOUTH MEETING, Pa. , Oct. 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy Poster by Dr. Matthew Morrow, VP of Translational Sciences at INOVIO Abstract Title: Reduction in Surgical Interventions for the Treatment of Recurrent Respiratory Papillomatosis by INO-3107 is Associated with Enriched Macrophage, Dendritic cell and T cell Signatures in Patient Airways Date and Time: October 19, 2024, 6:00 - 8:15pm ET Location: Boston, MA ISV Congress 2024 Oral presentation and poster by Dr. Michael Sumner, Chief Medical Officer at INOVIOAbstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP) Date and Time: October 22, 2024, 4:20pm KSTLocation: Seoul, Korea Fall Voice Poster by Dr. Jeffrey Skolnik, SVP of Clinical Development at INOVIOAbstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP) Date and Time: October 25 – October 26, 2024 Location: Phoenix, AZ World Vaccine Congress Europe Presentation and panel discussion by Dr. Dave Liebowitz, SVP Early-Stage Clinical Development at INOVIOTrack: Pre-Congress Workshop on Platform TechnologiesDate and Time: October 28, 2024, 10:00am CET Location: Barcelona, Spain Abstracts from these conferences will be made available on INOVIO's website following each presentation.

INOVIO to Present at Upcoming Scientific Conference
prnewswire.com17 September 2024 Sentiment: POSITIVE

PLYMOUTH MEETING, Pa. , Sept. 17, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conference: World Congress of Electroporation Oral Presentation by Trevor Smith, VP of Preclinical R&D at INOVIOAbstract Title: Development of in vivo-launched synthetic DNA-encoded antibodies employing CELLECTRA® electroporation technology Date and Time: September 18, 2024, 3:20pm – 3:35pm CET Location: Rome, Italy The abstract from the conference will be made available on INOVIO's website following the data presentation.

Inovio Pharmaceuticals, Inc. (INO) Q2 2024 Earnings Call Transcript
seekingalpha.com09 August 2024 Sentiment: NEUTRAL

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President & Chief Executive Officer Steve Egge - Chief Commercial Officer Michael Sumner - Chief Medical Officer Peter Kies - Chief Financial Officer Conference Call Participants Anish Nikhanj - RBC Capital Markets Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Yi Chen - H.C. Wainwright Operator Good afternoon ladies and gentlemen and welcome to the Inovio Second Quarter 2024 Financial Results Conference Call.

INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights
prnewswire.com08 August 2024 Sentiment: POSITIVE

PLYMOUTH MEETING, Pa. , Aug. 8, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter of 2024 and provided an update on recent company developments.

INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024
prnewswire.com25 July 2024 Sentiment: POSITIVE

PLYMOUTH MEETING, Pa. , July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that second quarter 2024 financial results will be released after the market close on August 8, 2024.

Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK
zacks.com12 July 2024 Sentiment: POSITIVE

Inovio (INO) soars 19% as its lead candidate, INO-3107, receives the innovative medicine tag under the U.K.'s Innovative Licensing and Access Pathway to treat recurrent respiratory papillomatosis.

INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway
prnewswire.com11 July 2024 Sentiment: POSITIVE

Award recognizes the potential for INO-3107 to be the first therapeutic option in the United Kingdom for patients suffering from Recurrent Respiratory Papillomatosis (RRP) PLYMOUTH MEETING, Pa. , July 11, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its lead DNA medicine candidate, INO-3107, has been designated an innovative medicine as part of the U.K.'s Innovative Licensing and Access Pathway (ILAP).

INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer
prnewswire.com02 July 2024 Sentiment: POSITIVE

Mr. Egge brings over 25 years of biopharmaceutical experience building commercial organizations and successfully launching novel therapeutic products INOVIO poised to become a commercial-stage company with plans to submit a Biologics License Application for INO-3107 in second half of 2024 under U.S. Food and Drug Administration's Accelerated Approval Pathway PLYMOUTH MEETING, Pa. , July 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the appointment of Steven Egge as Chief Commercial Officer.

  • 1(current)
  • 2

What type of business is Inovio Pharmaceuticals?

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

What sector is Inovio Pharmaceuticals in?

Inovio Pharmaceuticals is in the Healthcare sector

What industry is Inovio Pharmaceuticals in?

Inovio Pharmaceuticals is in the Biotechnology industry

What country is Inovio Pharmaceuticals from?

Inovio Pharmaceuticals is headquartered in United States

When did Inovio Pharmaceuticals go public?

Inovio Pharmaceuticals initial public offering (IPO) was on 08 December 1998

What is Inovio Pharmaceuticals website?

https://www.inovio.com

Is Inovio Pharmaceuticals in the S&P 500?

No, Inovio Pharmaceuticals is not included in the S&P 500 index

Is Inovio Pharmaceuticals in the NASDAQ 100?

No, Inovio Pharmaceuticals is not included in the NASDAQ 100 index

Is Inovio Pharmaceuticals in the Dow Jones?

No, Inovio Pharmaceuticals is not included in the Dow Jones index

When was Inovio Pharmaceuticals the previous earnings report?

No data

When does Inovio Pharmaceuticals earnings report?

The next expected earnings date for Inovio Pharmaceuticals is 08 November 2024